BACKGROUND Treatment decision making is strictly associated with the outcomes in patients with ischemic stroke who show a large core infarct.Medical care alone may result in suboptimal treatment efficacy,and endovascu...BACKGROUND Treatment decision making is strictly associated with the outcomes in patients with ischemic stroke who show a large core infarct.Medical care alone may result in suboptimal treatment efficacy,and endovascular treatment may be accompanied by safety issues.Whether endovascular treatment is superior to medical care is not well investigated in the clinical studies.AIM To investigate the efficacy of endovascular treatment and drug therapy alone in mild ischemic stroke patients with large infarct cores.METHODS Fifty patients with mild ischemic stroke and 50 patients with acute ischemic stroke caused by anterior large vessel occlusion were selected at the First Affiliated Hospital of Hebei North University between January 2021 and December 2021.Patients were divided into an endovascular therapy group and a drug therapy group according to different treatment methods.In the endovascular therapy group,there were 28 patients with minor stroke and 22 patients with large infarct cores.The drug therapy group had 22 patients with minor stroke and 28 patients with large infarct cores.The National Institutes of Health Stroke Scale(NIHSS) scores were collected and compared between the two groups immediately after the operation and 24 h and 7 d after the operation.The modified Rankin scale(m RS) and/or activity of daily living were assessed at hospital discharge.RESULTS There was no significant difference in NIHSS scores between the two groups before the operation(P > 0.05).NIHSS scores were lower in the endovascular therapy group than in the drug therapy group at 24 h and 7 d after the operation and at hospital discharge(all P < 0.05).The incidence of early neurologic deterioration was significantly lower in the endovascular therapy group than in the drug therapy group(P < 0.05).At hospital discharge,the m RS score was lower in the endovascular treatment group than in the drug therapy group,and the activity of daily living score was better in the endovascular treatment group than in the drug therapy group(all P < 0.05).During a follow-up of 3 mo,17 patients(34.0%) had good prognosis(m RS ≤ 2),33 patients(66.0%) had poor prognosis(m RS > 2),and 11 patients(22.0%) died.In the medical treatment group,16 patients(m RS ≤ 2) had good prognosis(32.0%),34 patients(m RS > 2) had poor prognosis(68.0%),and 14 patients(28.0%) died.There was no significant difference in prognosis and mortality between the two groups(P > 0.05).CONCLUSION Endovascular therapy can improve NIHSS score and m RS score in patients with mild ischemic stroke and large infarct cores.It is suitable for clinical application.展开更多
A waterproof nanocrystalline soft magnetic alloy core with a size of O.D.850 mm×I.D.316 mm×H.25 mm for radio frequency acceleration was successfully developed by winding 18μm 1k107b MA ribbons.Theμ'_(p...A waterproof nanocrystalline soft magnetic alloy core with a size of O.D.850 mm×I.D.316 mm×H.25 mm for radio frequency acceleration was successfully developed by winding 18μm 1k107b MA ribbons.Theμ'_(p)Qf products reached 7.5,10,and 12 GHz at 1,3,and 5 MHz,respectively.Theμ'_(p)Qf products of the MA core(O.D.250 mm×I.D.100 mm×H.25 mm)manufactured using a 13μm MA ribbon further increased by 30%.Detailed improvements on the MA core manufacture process are discussed herein.Continuous high-power tests on the new MA cores demonstrated its good performance of waterproofness,particularly its stability of highμ'_(p)Qf products.The MA core with highμ'pQf product and large size can operate under a high average RF power,high electric field,and in deionized water,which will be used in the China Spallation Neutron Source PhaseⅡ(CSNS-Ⅱ).展开更多
Objectives Endovascular therapy(EVT)now penetrates the once obscure realm of large infarct core volume acute ischaemic stroke(LICV-AIS).This research aimed to investigate the potential correlation between different an...Objectives Endovascular therapy(EVT)now penetrates the once obscure realm of large infarct core volume acute ischaemic stroke(LICV-AIS).This research aimed to investigate the potential correlation between different anaesthetic approaches and post-EVT outcomes in LICV-AIS patients.Methods Between October 2020 and May 2022,the China ANGEL-Alberta Stroke Programme Early CT Score(ASPECT)trial studied patients with LICV-AIS,randomly assigning them to the best medical management(BMM)or BMM with EVT.This post hoc subgroup analysis categorised subjects receiving BMM with EVT into general anaesthesia(GA)and non-GA groups based on anaesthesia type.We applied multivariable logistic regression to evaluate the relationship between anaesthesia during EVT and patient functional outcomes,as measured by the modified Rankin scale(mRS),in addition to the occurrence of complications.Further adjustment for selection bias was achieved through propensity score matching(PSM).Results In total,230 patients with LICV-AIS were enrolled(GA 84 vs Non-GA 146).No significant difference was observed between the two groups in terms of the proportion of patients who achieved an mRS score of 0-2 at 90 days(27.4%for the GA group vs 31.5%for the non-GA group,p=0.51).However,the GA group had significantly longer median surgical times(142 min vs 122 min,p=0.03).Furthermore,GA was associated with an increased risk of postoperative pneumonia(adjusted OR 2.03,95%CI 1.04 to 3.98).The results of PSM analysis agreed with the results of the multivariate regression analysis.No significant difference in intracranial haemorrhage incidence or mortality rate was observed between the groups.Conclusion This post hoc analysis of subgroups of the ANGEL-ASPECT trial suggested that there may be no significant association between the choice of anaesthesia and neurological outcomes in LICV-AIS patients.However,compared with non-GA,GA prolongs the duration of EVT and is associated with a greater postoperative pneumonia risk.展开更多
基金Supported by Scientific Research Fund of Hebei Health Commission 2022,No.20220591。
文摘BACKGROUND Treatment decision making is strictly associated with the outcomes in patients with ischemic stroke who show a large core infarct.Medical care alone may result in suboptimal treatment efficacy,and endovascular treatment may be accompanied by safety issues.Whether endovascular treatment is superior to medical care is not well investigated in the clinical studies.AIM To investigate the efficacy of endovascular treatment and drug therapy alone in mild ischemic stroke patients with large infarct cores.METHODS Fifty patients with mild ischemic stroke and 50 patients with acute ischemic stroke caused by anterior large vessel occlusion were selected at the First Affiliated Hospital of Hebei North University between January 2021 and December 2021.Patients were divided into an endovascular therapy group and a drug therapy group according to different treatment methods.In the endovascular therapy group,there were 28 patients with minor stroke and 22 patients with large infarct cores.The drug therapy group had 22 patients with minor stroke and 28 patients with large infarct cores.The National Institutes of Health Stroke Scale(NIHSS) scores were collected and compared between the two groups immediately after the operation and 24 h and 7 d after the operation.The modified Rankin scale(m RS) and/or activity of daily living were assessed at hospital discharge.RESULTS There was no significant difference in NIHSS scores between the two groups before the operation(P > 0.05).NIHSS scores were lower in the endovascular therapy group than in the drug therapy group at 24 h and 7 d after the operation and at hospital discharge(all P < 0.05).The incidence of early neurologic deterioration was significantly lower in the endovascular therapy group than in the drug therapy group(P < 0.05).At hospital discharge,the m RS score was lower in the endovascular treatment group than in the drug therapy group,and the activity of daily living score was better in the endovascular treatment group than in the drug therapy group(all P < 0.05).During a follow-up of 3 mo,17 patients(34.0%) had good prognosis(m RS ≤ 2),33 patients(66.0%) had poor prognosis(m RS > 2),and 11 patients(22.0%) died.In the medical treatment group,16 patients(m RS ≤ 2) had good prognosis(32.0%),34 patients(m RS > 2) had poor prognosis(68.0%),and 14 patients(28.0%) died.There was no significant difference in prognosis and mortality between the two groups(P > 0.05).CONCLUSION Endovascular therapy can improve NIHSS score and m RS score in patients with mild ischemic stroke and large infarct cores.It is suitable for clinical application.
基金supported by the funds of the National Natural Science Foundation of China (Nos. 11175194, 11875270, and U1832210)Youth Innovation Promotion Association CAS (No. 2018015)Guangdong Basic and Applied Basic Research Foundation (No.2019B1515120046)
文摘A waterproof nanocrystalline soft magnetic alloy core with a size of O.D.850 mm×I.D.316 mm×H.25 mm for radio frequency acceleration was successfully developed by winding 18μm 1k107b MA ribbons.Theμ'_(p)Qf products reached 7.5,10,and 12 GHz at 1,3,and 5 MHz,respectively.Theμ'_(p)Qf products of the MA core(O.D.250 mm×I.D.100 mm×H.25 mm)manufactured using a 13μm MA ribbon further increased by 30%.Detailed improvements on the MA core manufacture process are discussed herein.Continuous high-power tests on the new MA cores demonstrated its good performance of waterproofness,particularly its stability of highμ'_(p)Qf products.The MA core with highμ'pQf product and large size can operate under a high average RF power,high electric field,and in deionized water,which will be used in the China Spallation Neutron Source PhaseⅡ(CSNS-Ⅱ).
基金funded by Covidien Healthcare International Trading(Shanghai),Johnson&Johnson MedTech,Genesis MedTech(Shanghai)and Shanghai HeartCare Medical Technologysupported by the Clinical Medicine Development of Special Funding Support(ZYLX201708+2 种基金DFL20180502)the Beijing Municipal Science&Technology Commission(Z19110700660000)the Capital’s Funds for Health Improvement and Research(CFH 2024-2-2046).
文摘Objectives Endovascular therapy(EVT)now penetrates the once obscure realm of large infarct core volume acute ischaemic stroke(LICV-AIS).This research aimed to investigate the potential correlation between different anaesthetic approaches and post-EVT outcomes in LICV-AIS patients.Methods Between October 2020 and May 2022,the China ANGEL-Alberta Stroke Programme Early CT Score(ASPECT)trial studied patients with LICV-AIS,randomly assigning them to the best medical management(BMM)or BMM with EVT.This post hoc subgroup analysis categorised subjects receiving BMM with EVT into general anaesthesia(GA)and non-GA groups based on anaesthesia type.We applied multivariable logistic regression to evaluate the relationship between anaesthesia during EVT and patient functional outcomes,as measured by the modified Rankin scale(mRS),in addition to the occurrence of complications.Further adjustment for selection bias was achieved through propensity score matching(PSM).Results In total,230 patients with LICV-AIS were enrolled(GA 84 vs Non-GA 146).No significant difference was observed between the two groups in terms of the proportion of patients who achieved an mRS score of 0-2 at 90 days(27.4%for the GA group vs 31.5%for the non-GA group,p=0.51).However,the GA group had significantly longer median surgical times(142 min vs 122 min,p=0.03).Furthermore,GA was associated with an increased risk of postoperative pneumonia(adjusted OR 2.03,95%CI 1.04 to 3.98).The results of PSM analysis agreed with the results of the multivariate regression analysis.No significant difference in intracranial haemorrhage incidence or mortality rate was observed between the groups.Conclusion This post hoc analysis of subgroups of the ANGEL-ASPECT trial suggested that there may be no significant association between the choice of anaesthesia and neurological outcomes in LICV-AIS patients.However,compared with non-GA,GA prolongs the duration of EVT and is associated with a greater postoperative pneumonia risk.
